{
  "pmcid": "10638529",
  "sha256": "da61cff79159ea28d74d8bf6870103855c47840968c30bda4c99684ec2cf18ec",
  "timestamp_utc": "2025-11-09T23:08:12.696569+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 9.86981846473029,
    "reading_ease": 42.18627679806363,
    "word_count": 241
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Autofluorescence in Thyroidectomy"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Participants were randomised 1:1 to either the intervention group using Fluobeam® LX or a control group without it. The sample size calculation aimed to detect a reduction in low PTH rates from 15% to 5%, requiring 280 patients."
      },
      "Participants": {
        "score": 2,
        "evidence": "the trial included patients over 18 years scheduled for total thyroidectomy"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised 1:1 to either the intervention group using Fluobeam® LX or a control group without it."
      },
      "Objective": {
        "score": 1,
        "evidence": "This multicentre randomised controlled trial assessed the efficacy of Fluobeam® LX in visualizing parathyroid glands during total thyroidectomy to mitigate postoperative hypoparathyroidism."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the rate of low parathyroid hormone (PTH) levels on the first postoperative day."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was executed via the Eurocrine® platform, with allocation concealed from patients"
      },
      "Blinding": {
        "score": 1,
        "evidence": "allocation concealed from patients, ensuring a single-blinded design"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "From January 2021 to August 2022, 535 patients were randomised"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "535 patients were randomised, and 486 were analysed (246 intervention, 240 control)"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group had a 26.0% rate of low PTH levels compared to 32.1% in the control group (RR 0.81, 95% CI 0.61 to 1.07; p = 0.141)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No specific harm related to Fluobeam® LX was reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT04509011."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 22,
    "max_score": 25
  }
}